| 1 |
张建萍，李聪，魏玉辉，等. 美国器官移植临床药学服务内容和模式简介[J]. 中国现代应用药学，2021，38(4)：481-485.
|
| 2 |
刘冉佳，张志琪，黄文华，等. 肝移植儿童生命质量评估量表的系统综述[J]. 药物流行病学杂志，2022，31(4)：264-270.
|
| 3 |
Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases[J]. AMIA Annu Symp Proc, 2005：724-728.
|
| 4 |
van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping[J]. Scientometrics, 2010，84(2)：523-538.
|
| 5 |
Stratta RJ, Shaefer MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy[J]. Arch Surg, 1992，127(1)：55-63.
|
| 6 |
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis, 2020，71(6)：1367-1376.
|
| 7 |
Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[J]. Ther Drug Monit, 2019，41(3)：261-307.
|
| 8 |
Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing[J]. Clin Pharmacol Ther, 2015，98(1)：19-24.
|
| 9 |
Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation[J]. Transplantation, 2018，102(6)：900-931.
|
| 10 |
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019，33(9)：e13512.
|
| 11 |
Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference[J]. Ther Drug Monit, 2009，31(2)：139-152.
|
| 12 |
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I[J]. Clin Pharmacokinet, 2010，49(3)：141-175.
|
| 13 |
Shuker N, Bouamar R, van Schaik RH, et al. A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation[J]. Am J Transplant, 2016，16(7)：2085-2096.
|
| 14 |
Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients[J]. Am J Transplant, 2004，4(4)：611-620.
|
| 15 |
Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation[J]. Clin Pharmacokinet, 2014，53(2)：123-139.
|
| 16 |
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet, 2007，46(1)：13-58.
|
| 17 |
国家卫生健康委员会. 全国医疗服务项目技术规范(2023年版)[EB/OL]. (2023-09-28)[2024-9-11].
URL
|
| 18 |
国家卫生健康委员会办公厅. 关于开展驻科药师工作模式试点的通知[EB/OL]．(2024-01-08)[2024-09-11].
URL
|
| 19 |
Alloway RR, Dupuis R, Gabardi S, et al. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team[J]. Am J Transplant. 2011，11(8)：1576-1583.
|
| 20 |
Chandran MM, Cohen E, Doligalski CT, et al. The measure of impact: proposal of quality metrics for solid organ transplant pharmacy practice[J]. Am J Transplant, 2024，24(2)：164-176.
|
| 21 |
陈文倩，张雷，张弋，等. 实体器官移植他克莫司个体化治疗专家共识[J]. 中国医院用药评价与分析，2021，21(12)：1409-1424.
|
| 22 |
闫美玲，刘立玮，张弋. 药物基因组学与免疫抑制剂的个体化用药[J/OL]. 实用器官移植电子杂志，2017，5(1)：72-76.
|
| 23 |
Li J, Li Z. Differences and similarities in clinical pharmacy practice in China and the United States: a narrative review[J]. Eur J Hosp Pharm, 2018，25(1)：2-5.
|
| 24 |
马葵芬，朱硕，宋文彬，等. 移植药学门诊的建立及运行效果分析[J]. 今日药学，2018，28(12)：824-828.
|
| 25 |
Yin Z, Zhang W, Jia X, et al. " Access to pharmacy services is difficult in China" ：a qualitative study from the perspective of transplant recipients to explore their expectations[J]. BMC Health Serv Res, 2024，24(1)：387.
|